Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9915897 | 0.82 | CHRM2 (0.34) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL31481248 | 0.80 | TSHR (0.35) | — | |
| SCHEMBL2132631 | 0.79 | KLK7 (0.33) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL2132635 | 0.79 | KLK7 (0.33) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL3683653 | 0.77 | USP2 (0.37) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL13550896 | 0.77 | USP2 (0.37) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL13409204 | 0.76 | USP2 (0.40) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL3324495 | 0.75 | KLK7 (0.36) | USP2SMN1; SMN2KLK7NR1H2 | |
| SCHEMBL7132129 | 0.75 | KLK7 (0.36) | USP2SMN1; SMN2KLK7NR1H2 | |
| SCHEMBL3321284 | 0.74 | KLK7 (0.36) | KLK7KDM4EMAPTTHRBNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619037-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | Lerchen, Hans-Georg (DE) | 2025-09-24 | — | — | EP | disclosed |
| EP-4619044-A1 | ANTIBODY-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | Lerchen, Hans-Georg (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-20240423973-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | LERCHEN, HANS-GEORG (DE) | 2024-12-26 | — | — | US | disclosed |
| CN-118556062-A | Compounds, pharmaceutical compositions and methods for treating, preventing or managing hyperproliferative disorders | 文赛克斯制药有限责任公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2024105197-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | VINCERX PHARMA GMBH (DE) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024105206-A1 | ANTIBODY-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | VINCERX PHARMA GMBH (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-6492335-B1 | Glycoconjugates from modified camptothecin derivatives (20-O-linkage) | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20020173468-A1 | MODIFIED CYTOSTATIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423973-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | PCNA, TP53, BRCA1 | USP2 2846/4885SMN1; SMN2 4133/4885CHRM2 3377/4885 |
| US-20020173468-A1 | MODIFIED CYTOSTATIC AGENTS | TP53, PTMS, ANXA5 | USP2 3975/4885SMN1; SMN2 3872/4885CHRM2 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.